Tirzepatide, sold as Mounjaro, is an injectable medicine used with diet and exercise to improve blood sugar in adults with type 2 diabetes.
Quick summary
It acts through GIP and GLP-1 receptor pathways. It is not insulin, not a treatment for diabetic ketoacidosis, and not a do-it-yourself weight-loss product.
Key takeaways
- Mounjaro is FDA-approved for adults with type 2 diabetes.
- It can lower A1C and may reduce weight, but response varies.
- Low blood sugar risk can increase when used with insulin or sulfonylureas.
- Safety review should include thyroid cancer history, MEN2, pancreatitis symptoms, gallbladder problems, kidney risk during dehydration, and severe gastrointestinal symptoms.
Before starting
Review current medicines, glucose pattern, kidney function, eye history, gastrointestinal history, pregnancy plans, and cost. If insulin or a sulfonylurea is used, the clinician may need to reduce low-blood-sugar risk.
Mounjaro is injected under the skin. The label explains dosing, administration, storage, missed doses, and when it should not be used. Do not follow social media dosing advice or compounded-product instructions.
What to monitor
- Nausea, vomiting, diarrhea, or dehydration.
- Severe abdominal pain.
- Low blood sugar if using insulin or sulfonylurea.
- Worsening kidney function during severe illness.
- Any allergic reaction or symptoms that feel unsafe.
Practical takeaway
Tirzepatide can be a powerful type 2 diabetes tool, but the safest plan is individualized and monitored.
Safety note
This article is not a substitute for medical care. Seek urgent care for severe abdominal pain, severe dehydration, allergic reaction, severe low blood sugar, chest pain, or stroke symptoms.
What to ask your care team
- Why are we choosing tirzepatide for me?
- How will we reduce low-blood-sugar risk?
- What symptoms should make me stop and call?
Related reading
Source summary
- Drug Trials Snapshot: Mounjaro, U.S. Food and Drug Administration. Regulatory summary. Accessed June 5, 2026. Source
- Mounjaro Prescribing Information, U.S. Food and Drug Administration. Prescribing information. Accessed June 5, 2026. Source
- Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2026, American Diabetes Association. Clinical guideline. Accessed June 5, 2026. Source
- Cardiovascular Outcomes With Tirzepatide Versus Dulaglutide in Type 2 Diabetes, New England Journal of Medicine. Randomized clinical trial. Accessed June 5, 2026. Source